Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.
Open accessThe DOI matches its Crossref record.
Abstract
Expression of insulin-like growth factor I (IGF-I) mRNA by some tumor cell lines of neuroectodermal origin has been described. To further explore the significance of IGF-I mRNA expression in these tumors, a more extensive analysis was performed. Most (9 of 10) neuroectodermal tumor cell lines with a t(11;22) translocation (primitive neuroectodermal tumor [PNET], Ewing's sarcoma, esthesioneuroblastoma) expressed IGF-I mRNA, whereas 0 of 15 cell lines without the translocation (PNET, neuroblastoma) expressed IGF-I. Furthermore, inasmuch as all neuroblastoma (12 of 12) cell lines examined expressed IGF-II RNA, the pattern of IGF expression could distinguish between these closely related tumors. CHP-100, a PNET cell line with the t(11;22) translocation, was shown to secrete both IGF-I protein and an IGF binding protein, IGFBP-2. This cell line also expressed the type I IGF receptor mRNA, and blockade of this receptor by a monoclonal antibody (alpha IR3) inhibited serum-free growth. These data demonstrate that IGF-I expression is a property of neuroectodermal tumors with a t(11;22) translocation and that interruption of an IGF-I autocrine loop inhibits the growth of these tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Cheung, N.-K. V., & Dyer, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3526 · Cited by 801
Insulin-like Growth Factor Binding Proteins
Rechler, M. M. (1993) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)60444-6 · Cited by 755
The role of the insulin-like growth factors in the central nervous system
D’Ercole, A. J., Ye, P., Calikoglu, A. S., & Gutierrez-Ospina, G. (1996) · Molecular Neurobiology · doi:10.1007/bf02740625 · Cited by 447
Tolcher, A. W., Sarantopoulos, J., Patnaik, A., Papadopoulos, K., Lin, C.-C., Rodon, J., Murphy, B., Roth, B., McCaffery, I., Gorski, K. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6745 · Cited by 308
The Role of the Insulin-like Growth Factor System in Human Cancer
(1996) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60354-1 · Cited by 293
Riggi, N., & Stamenkovic, I. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.009 · Cited by 282
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133152 · Cited by 109
“Type I insulin-like growth factor receptor (IGF1R) is expressed in a wide range of solid tumors and hematologic malignancies [15, 16].”
BackgroundSelf-citationSensitivity of Ewing's sarcoma to TRAIL-induced apoptosis
Kontny, H. U., Hämmerle, K., Klein, R., Shayan, P., Mackall, C. L., & Niemeyer, C. M. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400836 · Cited by 90
“All cell lines have been characterized previously.(8,43,46) ± 49 They were maintained in RPMI supplemented with 10% FCS and 100 units/ml penicillin, 100 mg/ml streptomycin, and 4 mM glutamine.”
MethodKim, H.-Y., Ha Thi, H. T., & Hong, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.039 · Cited by 72
Metadata
- Authors
- Yee, D., Favoni, R. E., Lebovic, G. S., Lombana, F., Powell, D. R., Reynolds, C. P., & Rosen, N.
- Venue
- Journal of Clinical Investigation
- Published
- 1990-12-01
- Volume
- 86
- Issue
- 6
- Pages
- 1806-1814
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2054711858
- Cited by
- 175
- References
- 0
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.